Anti-Human CD64 (FCGR1) In Vivo Antibody - Ultra Low Endotoxin
Introducing the Anti-Human CD64 [Fcgr1] In Vivo Antibody - Ultra Low Endotoxin from Assay Genie, a highly specific and versatile monoclonal antibody designed for in vivo applications. This antibody targets the CD64 protein, a high-affinity receptor for the Fc region of IgG, making it essential for research in immunology, oncology, and related fields.
With the assurance of ultra-low endotoxin levels (<0.01 EU/μg), it is perfect for ELISA, flow cytometry, immunohistochemistry, and other precise assays. Available in various sizes, it is formulated in phosphate-buffered saline to ensure stability and efficacy. CD64, also known as Fc gamma receptor I (Fcgr1), is a glycoprotein prominently expressed on the surface of immune cells such as monocytes, macrophages, and neutrophils. It plays a significant role in the immune system, facilitating the phagocytosis of pathogens and the activation of immune responses through its high-affinity binding to IgG. Enhance your research and experimental outcomes with this dependable and high-performance antibody from Assay Genie.
Product Name:
Anti-Human CD64 (FCGR1) In Vivo Antibody - Ultra Low Endotoxin
Product Code:
IVMB0371
Size:
1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:
10.1
Protein:
CD64
Product Type:
Monoclonal Antibody
Synonyms:
FcgammaRI, FcR I, Fc Gamma Receptor Ia, Fc-Gamma RIA
Isotype:
IgG1 k
Reactivity:
Human
Applications:
B, FA, FC, IHC FF, In Vivo
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:
≤ 0.5 EU/mg as determined by the LAL method
Purity:
≥98% monomer by analytical SEC â‹… >95% by SDS Page
Product Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:
B, FA, FC, IHC FF, In Vivo
Reactivity:
Human
Host Species:
Mouse
Specificity:
Clone 10.1 recognizes the alpha subunit of human FCGR1.
Antigen Distribution:
FCGR1 is expressed on monocytes, macrophages, dendritic cells (DCs), and activated granulocytes.
Immunogen:
Rheumatoid synovial fluid cells and fibronectin purified human monocytes.
Concentration:
≥ 5.0 mg/ml
Endotoxin Level:
≤ 0.5 EU/mg as determined by the LAL method
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:
≥98% monomer by analytical SEC â‹… >95% by SDS Page
Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
FCGR1 antibody, 10.1, recognizes high-affinity immunoglobulin gamma Fc receptor I (FCGR1), also known as CD64. FCGR1 is a 72 kDa type I transmembrane glycoprotein expressed on monocytes, macrophages, and dendritic cells (DCs). FCGR1 can also be induced on neutrophils with IFNgamma and G-CSF1. FCGR1 binds with high affinity to monomeric IgG1 and IgG3, and to a lesser extent, IgG42, resulting in phosphorylation of the intracellular FCGR1 ITAM motif and subsequent recruitment of Syk. FCGR1 contributes to inflammation via several mechanisms, including promoting antibody-dependent cell-mediated cytotoxicity (ADCC), clearance of immune complexes, cytokine production, and antigen presentation1,3. CD64-based targeted therapies eliminate M1 pro-inflammatory macrophages and show clinical potential for the treatment of macrophage-mediated chronic inflammatory diseases, such as chronic cutaneous inflammation and rheumatoid arthritis4. In addition, CD64 promotes antitumor responses and mediates cytotoxic killing of tumor cells by macrophages5.
